Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy—Implications for Radiopharmaceutical Repurposing (Beyond Oncology)
Pharmaceutics · 03.09.2025 · 17 (9) · 1159
DOI: 10.3390/pharmaceutics17091159 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.09.2025. Verfasst von María Jimena Salgueiro und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Física, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The integration of nanotechnology into drug repurposing strategies is redefining the development landscape for diagnostic, therapeutic, and theranostic agents. In radiopharmacy, nanoplatforms are increasingly being explored to enhance or extend the use of existing radiopharmaceuticals, complementing earlier applications in other biomedical fields. Many of these nanoplatforms evolve into multifunctional systems by incorporating additional imaging modalities (e.g., MRI, fluorescence) or non-radioactive therapies (e.g., photodynamic therapy, chemotherapy). These hybrid constructs often emerge from the reformulation, repositioning, or revival of previously approved or abandoned compounds, generating entities with novel pharmacological, pharmacokinetic, and biodistribution profiles. However, their translational potential faces significant regulatory hurdles. Existing frameworks—typically designed for single-modality drugs or devices—struggle to accommodate the combined complexity of nanoengineering, radioactive components, and integrated functionalities. This review examines how these systems challenge current norms in classification, safety assessment, preclinical modeling, and regulatory coordination. It also addresses emerging concerns around digital adjuncts such as AI-assisted dosimetry and software-based therapy planning. Finally, the article outlines international initiatives aimed at closing regulatory gaps and provides future directions for building harmonized, risk-adapted frameworks that support innovation while ensuring safety and efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departamento de Física, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
- Instituto de Tecnología Farmacéutica y Biofarmacia (InTecFyB), Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires 1113, Argentina.
ORCID-Profile: Marcela Zubillaga
Zitieren
APA
Salgueiro, M. J., & Zubillaga, M. (2025). Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy—Implications for Radiopharmaceutical Repurposing (Beyond Oncology). Pharmaceutics, 17(9), 1159. https://doi.org/10.3390/pharmaceutics17091159
Vancouver
Salgueiro MJ, Zubillaga M. Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy—Implications for Radiopharmaceutical Repurposing (Beyond Oncology). Pharmaceutics. 2025;17(9):1159. doi:10.3390/pharmaceutics17091159
BibTeX
@article{Salgueiro2025,
author = {Salgueiro, María Jimena and Zubillaga, Marcela},
title = {Strategic Objectives of Nanotechnology-Driven Repurposing in Radiopharmacy—Implications for Radiopharmaceutical Repurposing (Beyond Oncology)},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {9},
pages = {1159},
doi = {10.3390/pharmaceutics17091159}
}
EUVIMED